Lab News

AACR 2024

Congratulations to Andrea and Caroline for the poster presentaions at the AACR in San DIego

Lab Meeting in La Cjaux-de-Fonds - November 2023

Well deserved dinner after a long day of presentations

PhD thesis defenses 2022

Congratulations to Dzhangar and Andrea for successfully defending their PhD!

Dzhangar defended his PhD on "Liposomal targeted drug delivery to rhabdomyosarcoma" on October 21 2022.

Andrea defended his PhD on "Chimeric Antigen Receptor (CAR) T cell therapy for rhabdomyosarcoma: novel targets identified by surfaceome profiling and promising pre-clinical efficacy targeting CD276 and FGFR4" on November 29 2022.

30.11.2022

21.10.2022 Dzhangar Dzhumashev

29.11.2022 Andrea Timpanaro

Quantum Dot-Based Screening Identifies F3 Peptide and Reveals Cell Surface Nucleolin as a Therapeutic Target for Rhabdomyosarcoma

Caroline and Andrea at the poster presentation

Caroline and Andrea presented their work at the CICON22 in NY City

The Sixth International Cancer Immunotherapy Conference was focused on Translating Science into Survival

Abstracts30.9.2022

Generous donation

Thank you to "Des Soleis pour princesse Mimi" for their continued support!

23.8.2022

Delivery and Targets for Pediatric Tumors

Hostellerie am Schwarzsee, Schwarzsee, Fribourg, 22-24.06.2019

Finally, after two years of forced pause, we could meet again with our friends from Montpelier, discuss about our common projects, and learn about new projects focused on silica nanoparticle design for cancer therapy and other diseases.

Group picture 2nd Symposium on Delivery and Targets for Pediatric Tumors, Schwarzsee, 2022

Presentations by young scientists

InnoMedica and NanoMedSyn

Location

Social

09.06.2022 Andrea receiving the award from Prof. Dr. med. Nicolas von der Weid, President of Childhood Cancer Switzerland.

22.03.2022

Andrea received his first research prize from Childhood Cancer Switzerland for his project:

"CD276/FGFR4 CAR T cell therapy for rhabdomyosarcoma – pre-clinical in vivo studies"

CONGRATS!

Congratulations to Caroline for winning the Biomedical Science Award 2022 from the Swiss University in Bern

The prize was awarded to the three best Master Students by CSL Behring on 11 April 2022.

Congratulations to Andrea for the prize for Best Presentation in Translational Research!

All very happy at the reception!
(From the left: Prof. Matthias Kopp, Andrea Timpanaro, Prof. Christa Flück, PD Michele Bernasconi

All very happy at the reception!
now with Prof. Jochen Rössler

Dzhangar presented successfully his latest work at the online Phospholipid Symposium

10.11.2020 - New paper by Nagjie is out in Cancers

Thank you all for your contribution!

Novel FGFR4-Targeting Single-Domain Antibodies for Multiple Targeted Therapies against RhabdomyosarcomaThe fibroblast growth factor receptor 4 (FGFR4) is overexpressed in rhabdomyosarcoma (RMS) and represents a promising target for treatments based on specific and efficient antibodies. Despite progress, there is an urgent need for targeted treatment options to improve survival rates, and to limit long-term side effects. From phage display libraries we selected FGFR4-specific single-domain antibodies (sdAb) binding to recombinant FGFR4 and validated them by flow cytometry, surface plasmon resonance, and fluorescence microscopy. The specificity of the selected sdAb was verified on FGFR4-wild type and FGFR4-knock out cells. FGFR4-sdAb were used to decorate vincristine-loaded liposomes and to generate chimeric antigen receptor (CAR) T cells. First, incubation of RMS cells with FGFR4-sdAb revealed that FGFR4-sdAb can block FGF19-FGFR4 signaling via the MAPK pathway and could therefore serve as therapeutics for FGFR4-dependent cancers. Second, FGFR4-targeted vincristine-loaded liposomes bound specifically to RMS cells and were internalized by the receptor, demonstrating the potential for active drug delivery to the tumor. Third, FGFR4-CAR T cells, generated with one sdAb candidate, demonstrated strong and specific cytotoxicity against FGFR4 expressing RMS cells. We selected novel FGFR4-sdAb with high specificity and nano- to picomolar affinities for FGFR4 which have the potential to enable multiple FGFR4-targeted cancer therapy approaches.

2.11.2020 - INNOVATION Network News.

New hopes for paediatric soft tissue sarcomas | Innovation News NetworkDr Michele Bernasconi from the University of Bern discusses nanomedicine and immunotherapies for treating paediatric soft tissue sarcomas.

Charity Event

by the Foundation Des Soleils pour Princesse Mimi

9.11.2019 - At the Espace Perrier de Marin.

Thankfully accepting the generous donation.

(From the left: Mme Floriane Weiss, Dzhangar Dzhumashev, Michele Bernasconi, Andrea Timpanaro, Mme Janie Xenarios (President))

First Symposium on Delivery and Targets for Pediatric Tumors

Palavas, Institut St. Pierre , 13.06.2019

Page updated

Google Sites

Report abuse